Overview

Stem Cell Transplant for Hematological Malignancy

Status:
Terminated

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.

Phase:

N/A

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Treatments:

Busulfan
Cyclophosphamide